This trial is evaluating whether Stereotactic Body Radiation Therapy will improve 1 primary outcome, 7 secondary outcomes, and 3 other outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of At transplantation.
This trial requires 15 total participants across 2 different treatment groups
This trial involves 2 different treatments. Stereotactic Body Radiation Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Cancers, hepatocellular, of which carcinoma of the liver is the second-largest group, affect about one million people in the United States. Carcinoma of the hepatocellular type is not a common occurrence, accounting for around one third of all hepatoblastomas/hepatoid tumours and about two thirds of all cholangiocarcinomas/sclerosing cholangitis.
Multiple environmental factors, such as diet, alcohol and tobacco, may contribute to the development of hepatocellular carcinoma. One meta-analysis suggested that excess hepatocellular carcinoma could develop from a hepatitis-B virus (HBV) infection, suggesting a synergistic effect of both factors.
It does not mean that patients can be cured of liver carcinoma, but liver carcinoma can be cured. The mainstay is adequate management, using multidisciplinary approaches and combining the management strategies. In order of treatment, chemotherapy, surgery and radiotherapy are effective means.
The present practice of treating some types of HCC with chemotherapeutics, RFI, hormonal therapy, or curative operation is still debated. Based on the data presented, combination chemotherapy may be the preferred treatment for HCC in patients who have not received treatment.
Overall, the risk of hepatocellular carcinoma is estimated to be 0.13, which is relatively low when considering its prevalence and mortality. However, the incidence of this carcinoma has steadily increased since the early 1980s and appears to justify a nationwide screening program.
Genetic abnormalities associated with familial HCC may be different from those found in sporadic HCC. Results from a recent clinical trial have implications for the development of diagnostic and prophylactic methods for HCAs.
Stereotactic body radiation therapy is commonly used for treatment of HCC, and the use of radiotherapy with a second modality, with or without chemotherapy, may be the most relevant factors that influence the treatment and prognosis of patients with HCC.
SBRT is an effective treatment for hepatic tumors, both for locoregional control and disease-free survival. Local complications are well tolerated, but long-term studies are needed to address the potential for long-lasting liver dysfunction.
The cause of carcinoma, hepatocellularis unknown. Possible causes include a chronic inflammatory stimulus or chronic oxidative stress of the liver stimulating chronic cirrhosis with increased tissue fibrosis as the underlying underlying pathogenesis.
In patients with localized hepatocellular carcinoma who are able to tolerate treatment in a short period of time with very low toxicity and an excellent functional outcome, SBRT achieves comparable efficacy with conventional external-beam techniques. SBRT in HCC patients with larger lesions (≤ 5 cm.) is better absorbed than conventional external-beam techniques, but not as good if doses are restricted. Higher doses, either using SBRT or using external beam techniques with or without additional proton therapy, can be used safely to achieve similar antitumor response but with a reduced risk of toxicity.
A variety of other causes must be excluded before a specific diagnosis can be made. Patients with focal septal, sinus, nodular, or solid hepatoma or with other types of carcinoma can present with advanced stage disease because the disease has already metastasized. Patients with focal solid, nodular, or sinus HCC should also be evaluated carefully to exclude the possibility that the tumor is metastatic. To be certain of the diagnosis of carcinoma, hepatocellular, a biopsy is mandatory. However, the usefulness of a biopsy is less accurate if it is done too early.